Bone Biologics Corporation has reported its financial results for the fiscal year ending December 31, 2025, revealing a net loss of $3.1 million, a decrease of 24.4% from the previous year's loss of $4.1 million. The company did not generate any revenue during this period, consistent with its ongoing development stage. Total operating expenses decreased by 23.3% to $3.2 million, primarily due to a significant reduction in research and development costs, which fell by 50.2% to $1.1 million as the company streamlined its operations in preparation for a pivotal clinical study.
In terms of strategic developments, Bone Biologics has made notable progress with its lead product candidate, the NELL-1/DBM Fusion Device, which is currently undergoing a multicenter, prospective, randomized pilot clinical study in Australia. This study aims to evaluate the safety and effectiveness of the device in treating degenerative disc disease in adult subjects. The company has successfully treated the first subjects in this study, marking a significant milestone in its clinical development efforts. The study's design has received prior approval from the FDA, indicating a positive regulatory outlook.
Operationally, Bone Biologics has seen a substantial increase in its cash position, ending the year with $5.3 million compared to $3.3 million in 2024. This increase was bolstered by a public offering completed in June 2025, which raised approximately $4.4 million in net proceeds. The company also utilized an At The Market (ATM) offering, generating additional funds. As of December 31, 2025, the company had 1,795,260 shares of common stock outstanding, reflecting a reverse stock split executed in June 2025.
Looking ahead, Bone Biologics faces challenges related to its ongoing need for capital to fund its operations and clinical trials. The company has expressed substantial doubt about its ability to continue as a going concern, as it has incurred cumulative losses of approximately $88.1 million since its inception. Management anticipates that available cash will fund operations into the fourth quarter of 2026, but additional financing will be necessary to support future development activities. The company is actively seeking to raise further capital through equity or debt financing, although there are no assurances that such financing will be available on favorable terms.
In summary, Bone Biologics Corporation is navigating a critical phase in its development with ongoing clinical trials and a focus on securing additional funding. The company's financial performance reflects a strategic reduction in expenses, while its operational milestones indicate progress in bringing its innovative bone regeneration technology to market.
About Bone Biologics Corp
Bone Biologics Corporation develops recombinant human protein-based medical devices for bone regeneration, focusing on spinal fusion using its proprietary NELL-1 protein combined with demineralized bone matrix (DBM). Targeting orthopedic and spinal surgery markets, the company’s platform aims to improve bone growth outcomes with a safer, targeted approach. Its business model centers on clinical development, regulatory approval, and commercialization of osteopromotive biologics for surgeons and patients with bone defects.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.